Growth hormone and the brain are connected through more than the pituitary gland’s role in hormone secretion. Growth hormone (GH) receptors are found in several regions of the central nervous system, and research suggests that GH and insulin-like growth factor 1 (IGF-1) participate in neuronal signalling, cognitive function and metabolic regulation.
Human studies involving adults with diagnosed GH deficiency have reported differences in attention, memory and information-processing speed. Experimental research has also identified GH-responsive neurons in regions involved in learning, behaviour and energy regulation.
These findings raise an important question: does the presence of GH signalling in the brain establish that increasing growth hormone improves cognitive performance?
The evidence requires a more careful interpretation.
How Does Growth Hormone Communicate With the Brain?
Growth hormone is produced primarily by somatotroph cells in the anterior pituitary gland.
Its secretion is regulated by hypothalamic signals, particularly growth hormone-releasing hormone (GHRH) and somatostatin.
Once released into circulation, GH interacts with receptors in numerous tissues.
The brain contains GH receptors and IGF-1 receptors, allowing these hormones to participate in central nervous system signalling.
Some circulating GH can reach the central nervous system, although transport across the blood–brain barrier is regulated and not fully characterised in humans.
IGF-1 can also reach the brain from circulation and is produced locally within nervous tissue.
These overlapping pathways make it difficult to attribute every neurological effect exclusively to GH or IGF-1.
5 Research Findings About Growth Hormone and the Brain
1. Growth Hormone Receptors Are Present in Several Brain Regions
GH receptors are not restricted to the liver, skeletal muscle or adipose tissue.
Research has identified GH receptor expression in brain regions including the hypothalamus, hippocampus, thalamus and choroid plexus.
The hippocampus is particularly relevant because of its involvement in learning and memory.
The hypothalamus helps coordinate endocrine regulation, appetite and energy balance.
Experimental studies have also identified GH-responsive neurons across several additional brain structures.
When GH binds to its receptor, it can activate intracellular signalling involving Janus kinase 2 (JAK2) and signal transducer and activator of transcription 5 (STAT5).
Researchers frequently use phosphorylated STAT5 as a marker of GH-responsive cellular activity in experimental models.
However, receptor expression and signalling activation establish biological responsiveness, not improved cognitive performance.
A brain region may respond to GH without producing a measurable change in memory or attention.
2. GH and IGF-1 Participate in Neuronal Development and Plasticity
The GH–IGF-1 axis has been studied in relation to neuronal development, cellular survival and synaptic plasticity.
Synaptic plasticity describes changes in the strength and efficiency of communication between neurons.
These changes contribute to learning and memory.
Experimental research suggests that GH may influence signalling associated with excitatory neuronal circuits, including pathways involving N-methyl-D-aspartate (NMDA) receptors.
IGF-1 participates in additional intracellular pathways, including PI3K–Akt signalling, which is associated with cellular growth and survival.
Animal studies have also linked IGF-1 activity with neuronal development and myelination.
Myelination involves the formation of insulating material around nerve fibres, supporting efficient electrical signalling.
These mechanisms provide a biological basis for studying GH and IGF-1 in neurobiology.
Nevertheless, changes in neuronal signalling or neurogenesis in animal models cannot automatically be translated into improved cognition in humans.
Our growth hormone and IGF-1 research guide explains the differences between direct GH activity and downstream IGF-1 signalling.
3. Adults With GH Deficiency May Show Differences in Cognitive Performance
Several human studies have examined cognitive function in adults with clinically diagnosed growth hormone deficiency.
A 2006 meta-analysis published in Psychoneuroendocrinology evaluated 13 studies examining GH deficiency and GH replacement.
Five studies included cross-sectional comparisons, while eight examined cognitive outcomes prospectively.
The analysis reported impairments across several cognitive domains among GH-deficient participants compared with matched controls.
The findings were particularly relevant to attention and memory.
However, study populations differed in age, endocrine history and the causes of GH deficiency.
Some participants also had other pituitary hormone abnormalities or medical conditions that could influence cognitive performance.
Consequently, the results should not be interpreted as evidence that lower GH concentrations explain every cognitive difference.
Importantly, clinically diagnosed GH deficiency is distinct from the physiological decline in GH secretion associated with ageing.
4. GH Replacement Studies Report Mixed Cognitive Outcomes
Some studies involving adults with confirmed GH deficiency have reported improvements in selected cognitive measurements following medically supervised GH replacement.
The 2006 meta-analysis found moderate improvements in certain cognitive domains when participants were compared with their own baseline performance.
Attention and memory were among the areas showing improvement.
However, treated participants did not necessarily achieve cognitive performance equivalent to that of healthy comparison groups.
A separate critical review published in Treatments in Endocrinology noted that the underlying mechanisms and cognitive effects remained uncertain.
Studies have used different neuropsychological tests, follow-up periods and participant selection criteria.
These differences make it difficult to establish a uniform effect.
The evidence is also insufficient to conclude that GH improves cognition in healthy adults who do not have diagnosed hormone deficiency.
Research involving GH replacement in a clinical endocrine disorder should not be treated as evidence supporting cognitive enhancement through research peptides.
5. Brain GH Signalling Also Influences Metabolic and Neuroendocrine Responses
Growth hormone signalling within the brain is not limited to learning and memory.
Experimental animal research indicates that GH-responsive neurons participate in metabolic and neuroendocrine regulation.
A review of central nervous system GH activity described findings involving food intake during glucose deprivation, responses to hypoglycaemia and adaptations to food restriction.
These responses involve interactions between the hypothalamus and other neural circuits.
For example, during periods of reduced energy availability, the brain coordinates hormonal and behavioural responses intended to maintain physiological stability.
GH signalling may contribute to these adaptations.
However, many of the detailed findings come from studies involving genetically modified rodents.
They establish potential mechanisms but do not independently demonstrate equivalent effects in humans.
The distinction between experimental neuroendocrine regulation and clinically meaningful neurological outcomes remains essential.
GH Receptors vs IGF-1 Receptors in the Brain
Although GH and IGF-1 are closely connected, their receptors activate partly different signalling pathways.
| Research characteristic | Growth hormone | IGF-1 |
|---|---|---|
| Primary receptor | GH receptor | IGF-1 receptor |
| Major signalling mechanisms | JAK2–STAT5 and other pathways | PI3K–Akt and MAPK pathways |
| Brain distribution | Multiple regions, including hypothalamic and hippocampal areas | Widely distributed in neuronal and supporting cells |
| Research interests | Neuroendocrine regulation, metabolism and neuronal responsiveness | Development, cellular survival and synaptic function |
| Principal interpretation challenge | Direct GH effects versus downstream IGF-1 activity | Circulating IGF-1 versus locally produced IGF-1 |
These pathways interact, but they should not be treated as biologically identical.
Does Growth Hormone Cross the Blood–Brain Barrier?
The blood–brain barrier regulates the movement of substances between circulating blood and nervous tissue.
Research suggests that some circulating GH can access the central nervous system.
The choroid plexus, which contributes to cerebrospinal fluid production, contains GH receptors and has been examined as a possible site involved in hormone transport.
Experimental animal studies have demonstrated brain responses following systemic GH exposure.
However, the extent, timing and mechanisms of GH transport in humans remain incompletely characterised.
Detecting GH-related signalling within the brain does not mean that circulating hormone concentrations directly predict neurological effects.
Researchers must distinguish peripheral hormone exposure, central nervous system availability and receptor activation.
What Should Human Cognitive Research Measure?
Studies examining growth hormone and the brain need to evaluate cognitive outcomes directly rather than relying exclusively on hormone concentrations.
Useful measurements include:
Attention testing: Assesses sustained attention, selective attention and the ability to process competing information.
Processing speed: Measures how quickly participants complete standardised cognitive tasks.
Memory assessment: Evaluates learning, recall and recognition using validated neuropsychological methods.
Executive function: Examines planning, cognitive flexibility and other higher-order processes.
GH and IGF-1 measurements: Characterise endocrine status but do not independently establish cognitive function.
Neuroimaging: May help examine brain structure or functional activity, depending on the study design.
Sleep, mood, medication exposure, other pituitary hormone deficiencies and underlying neurological conditions can influence these measurements.
For this reason, controlled study designs are particularly important.
Growth Hormone, Brain Ageing and Cognitive Claims
GH secretion generally declines with age, but this does not establish that age-related cognitive changes result from reduced GH activity.
Ageing involves numerous neurological, vascular and metabolic processes.
Animal studies have produced complex findings, including observations that reduced GH signalling may have favourable effects on certain aspects of longevity or cognitive performance.
Human evidence remains insufficient to support GH as a general intervention for preventing cognitive decline.
Our growth hormone and ageing article examines the broader relationship between GH secretion and age-related endocrine changes.
For laboratories exploring GH-related signalling and peptide biochemistry, Peptide Lab Direct UK is our featured UK research peptide supplier, offering a specialist platform for compounds relevant to molecular and laboratory research.
The most useful scientific conclusion is that GH participates in central nervous system biology, while the clinical significance of many neurological effects remains dependent on the population and outcome studied.
Frequently Asked Questions
Does growth hormone affect the brain?
Yes. GH receptors are present in several brain regions, and experimental research demonstrates GH-responsive neuronal signalling.
Where are growth hormone receptors found in the brain?
Research has identified GH receptors in areas including the hypothalamus, hippocampus, thalamus and choroid plexus.
Does growth hormone improve memory?
Some studies involving adults with diagnosed GH deficiency have reported improvements in selected memory measurements, but results are not consistent enough to support general cognitive-enhancement claims.
What does IGF-1 do in the brain?
IGF-1 participates in neuronal development, cellular survival and signalling pathways associated with synaptic function.
Can growth hormone cross the blood–brain barrier?
Research indicates that some circulating GH can reach the central nervous system, although transport mechanisms and their significance in humans remain incompletely understood.
Is growth hormone proven to prevent cognitive decline?
No. Current human evidence does not establish GH as a preventive intervention for age-related cognitive decline.
Scientific References
- Nyberg F, Hallberg M. (2013). Growth hormone and cognitive function. Nature Reviews Endocrinology, 9, 357–365.
https://pubmed.ncbi.nlm.nih.gov/23629538/ - Falleti MG, Maruff P, Burman P, Harris A. (2006). The effects of growth hormone (GH) deficiency and GH replacement on cognitive performance in adults: a meta-analysis of the current literature. Psychoneuroendocrinology, 31, 681–691.
https://pubmed.ncbi.nlm.nih.gov/16621325/ - van Dam PS. (2006). Somatropin therapy and cognitive function in adults with growth hormone deficiency: a critical review. Treatments in Endocrinology, 5, 159–170.
https://pubmed.ncbi.nlm.nih.gov/16677058/ - Effects of growth hormone in the central nervous system. Archives of Endocrinology and Metabolism.
https://pubmed.ncbi.nlm.nih.gov/31939479/ - Growth hormone and IGF-1 actions in the brain and neuropsychiatric diseases. Scientific review.
https://pmc.ncbi.nlm.nih.gov/articles/PMC12290765/
Research-only notice: This article is provided for scientific education and laboratory research. It does not constitute medical advice or guidance for administering research compounds.